VAROGLUTAMSTAT

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H20N4O2
Molecular Weight	336.3877
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of VAROGLUTAMSTAT

Structure Search

SMILES

CCCOC1=CC=C(C=C1)[C@H]2CNC(=O)N2C3=CC4=C(NC=N4)C=C3

InChI

InChIKey=XHIKZWOEFZENIX-GOSISDBHSA-N

InChI=1S/C19H20N4O2/c1-2-9-25-15-6-3-13(4-7-15)18-11-20-19(24)23(18)14-5-8-16-17(10-14)22-12-21-16/h3-8,10,12,18H,2,9,11H2,1H3,(H,20,24)(H,21,22)/t18-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C19H20N4O2
Molecular Weight	336.3877
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:54:29 GMT 2023` Edited by `admin` on `Sat Dec 16 16:54:29 GMT 2023`
Record UNII	E3DSH8LL4L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VAROGLUTAMSTAT

Official Name

English

(5S)-1-(1H-BENZIMIDAZOL-5-YL)-5-(4- PROPOXYPHENYL)IMIDAZOLIDIN-2-ONE

Systematic Name

English

2-IMIDAZOLIDINONE, 1-(1H-BENZIMIDAZOL-6-YL)-5-(4-PROPOXYPHENYL)-, (5S)-

Systematic Name

English

varoglutamstat [INN]

Common Name

English

PQ-912

Code

English

PQ912

Code

English

(S)-1-(1H-BENZIMIDAZOL-5-YL)-5-(4-PROPOXYPHENYL)IMIDAZOLIDIN-2-ONE

Systematic Name

English

Code System Code Type Description

PUBCHEM

51030870

Created by admin on Sat Dec 16 16:54:30 GMT 2023 , Edited by admin on Sat Dec 16 16:54:30 GMT 2023

PRIMARY

FDA UNII

E3DSH8LL4L

Created by admin on Sat Dec 16 16:54:30 GMT 2023 , Edited by admin on Sat Dec 16 16:54:30 GMT 2023

PRIMARY

NCI_THESAURUS

C179133

Created by admin on Sat Dec 16 16:54:30 GMT 2023 , Edited by admin on Sat Dec 16 16:54:30 GMT 2023

PRIMARY

SMS_ID

300000006000

Created by admin on Sat Dec 16 16:54:30 GMT 2023 , Edited by admin on Sat Dec 16 16:54:30 GMT 2023

PRIMARY

CAS

1276021-65-8

Created by admin on Sat Dec 16 16:54:30 GMT 2023 , Edited by admin on Sat Dec 16 16:54:30 GMT 2023

PRIMARY

CLINICAL_TRIALS.GOV

NCT03919162

Created by admin on Sat Dec 16 16:54:30 GMT 2023 , Edited by admin on Sat Dec 16 16:54:30 GMT 2023

PRIMARY

INN

11664

Created by admin on Sat Dec 16 16:54:30 GMT 2023 , Edited by admin on Sat Dec 16 16:54:30 GMT 2023

PRIMARY

INN

Related Record Type Details


					MA5AQ51HF3

HUMAN .BETA.-AMYLOID PEPTIDE (PGLU3-42)

TARGET->INHIBITOR OF EXPRESSION

Amount:


					NFZ9GEM9QP

HUMAN .BETA.-AMYLOID PEPTIDE (PGLU3-40)

TARGET->INHIBITOR OF EXPRESSION

Amount:


					A976YD4N0Y

VAROGLUTAMSTAT HYDROCHLORIDE

SALT/SOLVATE -> PARENT

Amount:


					LE02PUG6BH

GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE

TARGET -> INHIBITOR

Amount:


					17I3DH51XQ

C-C MOTIF CHEMOKINE 2

TARGET->INHIBITOR OF EXPRESSION

Comments:

Inhibit conversion of N-terminal Q to pE. formation of pE was prevented by inhibiting isoQC, CCL2 was more prone to N-terminal degradation, which resulted in less functional CCL2 activity. This had the net effect of decreasing monocyte infiltration in vivo, resulting in decreased lung inflammation,

Interaction Type:

IN-VIVO

Amount:


					FBS88VEF1N

RACEMATE -> ENANTIOMER

Amount:


					17I3DH51XQ

C-C MOTIF CHEMOKINE 2

TARGET -> INHIBITOR

Comments:

Inhibit conversion of N-terminal Q to pE. formation of pE was prevented by inhibiting isoQC, CCL2 was more prone to N-terminal degradation, which resulted in less functional CCL2 activity. This had the net effect of decreasing monocyte infiltration in vivo, resulting in decreased lung inflammation.

Interaction Type:

IN-VITRO

Amount:

Related Record Type Details


					E3DSH8LL4L

ACTIVE MOIETY

Amount: